Advice

In the absence of a submission from the holder of the marketing authorisation:

daptomycin (Cubicin®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia associated with complicated skin and soft-tissue infections.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting.  As a result we cannot recommend its use within NHSScotland.

Download detailed advice135KB (PDF)

Download

Medicine details

Medicine name:
daptomycin (Cubicin)
SMC ID:
1309/18
Indication:
Treatment of paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia associated with complicated skin and soft-tissue infections.
Pharmaceutical company
MSD
BNF chapter
Infections
Submission type
Non submission
Status
Not recommended
Date advice published:
12 February 2018